Semaglutide is effectively tolerated with no hazard of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse consequences. A significant populace afflicted with COVID-19 infection were being diabetic; hence use of semaglutide in diabetic issues together with CV clients would be very